Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2026 | EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer

Tian Zhang • 1 Jun 2026
ASCO 2026
Bladder Cancer Genitourinary Cancer Antibodies Atezolizumab Cisplatin Enfortumab vedotin Pembrolizumab
EV-303 EV-304 IMvigor011

Tian Zhang, MD, of UT Southwestern Medical Center, discusses the growing role of enfortumab vedotin plus pembrolizumab in muscle-invasive bladder cancer, highlighting perioperative trial data demonstrating improved event-free survival (EFS) and high pathologic complete response rates (pCR) across cisplatin eligibility groups. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Tian Zhang

Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
BOOST-RCC: evolocumab and nivolumab in metastatic renal cell carcinoma
1:51
BOOST-RCC: evolocumab and nivolumab in metastatic renal cell carcinoma
Tian Zhang • 28 Feb 2026
Overcoming resistance to frontline immunotherapy in kidney cancer
0:57
Overcoming resistance to frontline immunotherapy in kidney cancer
Tian Zhang • 28 Feb 2026

Related Videos

Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
3:04
Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
Andrew Armstrong • 3 Jun 2026
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
2:24
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
Andrew Armstrong • 3 Jun 2026
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals